<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2020000400014</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2020000400014</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Urea como alternativa terapéutica a tolvaptán en el tratamiento de la hiponatremia: reporte de caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Urea as a therapeutic alternative to tolvaptan in the treatment of hyponatremia: case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferrer-Machín]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-García]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Plasencia-García]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Merino-Alonso]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Nuestra Señora de Candelaria Servicio de Farmacia Hospitalaria ]]></institution>
<addr-line><![CDATA[Santa Cruz de Tenerife ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario Nuestra Señora de Candelaria Servicio de Nefrología ]]></institution>
<addr-line><![CDATA[Santa Cruz de Tenerife ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>30</volume>
<numero>4</numero>
<fpage>339</fpage>
<lpage>341</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2020000400014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2020000400014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2020000400014&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Los pacientes con secreción inadecuada de hormona antidiurética (SIADH) son propensos a sufrir hiponatremia. El tolvaptán está indicado en adultos para el tratamiento de hiponatremia secundaria al SIADH. Sin embargo la urea se propone como una buena opción terapéutica para el aumento de los niveles de sodio. En este documento informamos del caso de una paciente con hiponatremia asociada a SIAH que es tratado con tolvaptán consiguiendo una concentración plasmática de sodio muy variable. Parece ser que la urea puede contribuir a un mejor control de los niveles de sodio con un ascenso más lento, progresivo y estable, proporcionando mayor seguridad a nuestra paciente y logrando además reducción de costes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY Patients with inadequate antidiuretic hormone secretion (SIADH) are prone to hyponatremia. Tolvaptan is indicated in adults for the treatment of hyponatremia secondary to SIADH. However, urea is proposed as a good therapeutic option for increasing sodium levels. In this document we report the case of a patient with hyponatremia associated with SIAH who is treated with tolvaptan, achieving a highly variable plasma sodium concentration. It seems that urea can contribute to a better control of sodium levels with a slower, progressive and stable rise, providing greater safety to our patient and also achieving cost reduction.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hiponatremia]]></kwd>
<kwd lng="es"><![CDATA[secreción inadecuada de hormona antidiurética]]></kwd>
<kwd lng="es"><![CDATA[urea]]></kwd>
<kwd lng="en"><![CDATA[Hyponatremia]]></kwd>
<kwd lng="en"><![CDATA[inadequate antidiuretic hormone secretion]]></kwd>
<kwd lng="en"><![CDATA[urea]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spasovski]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vanholder]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Allolio]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Annane]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ball]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bichet]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Decaux]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fenske]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Hoorn]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ichai]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Joannidis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Soupart]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zietse]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Haller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Veer]]></surname>
<given-names><![CDATA[S van der]]></given-names>
</name>
<name>
<surname><![CDATA[Biesen]]></surname>
<given-names><![CDATA[W van]]></given-names>
</name>
<name>
<surname><![CDATA[Nagler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Espinoza]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía de práctica clínica sobre el diagnóstico y tratamiento de la hiponatremia]]></article-title>
<source><![CDATA[Nefrología]]></source>
<year>2017</year>
<volume>37</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>370-80</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Librizzi]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Auñón Rubio]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Torralba Morrón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trastornos del equilibrio hidroelectrolítico. Síndrome de secreción inadecuada de hormona antidiurética. Fluidoterapia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Suárez Pita]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas Romero]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Salas Jarque]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual de Diagnóstico y Terapéutica Médica]]></source>
<year>2016</year>
<edition>8ª</edition>
<page-range>1127-50</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schrier]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gheorghiade]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berl]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Verbalis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Czerwiec]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Orlandi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia.]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2006</year>
<volume>355</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2099-112</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<collab>Agencia Europea del Medicamento y Productos Sanitarios (AEMPS</collab>
<source><![CDATA[Samsca®. Ficha Técnica del medicamento]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="">
<source><![CDATA[Samsca (Tolvaptan): Drug Safety Communication - FDA Limits Duration and Usage Due To Possible Liver Injury Leading to Organ Transplant or Death]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<source><![CDATA[Samsca (tolvaptan): Drug Warning - Potential Risk of Liver Injury]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
